These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 21120554)

  • 1. Exploration of the binding of proton pump inhibitors to human P450 2C9 based on docking and molecular dynamics simulation.
    Shi R; Li J; Cao X; Zhu X; Lu X
    J Mol Model; 2011 Aug; 17(8):1941-51. PubMed ID: 21120554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploration of the binding of curcumin analogues to human P450 2C9 based on docking and molecular dynamics simulation.
    Shi R; Wang Y; Zhu X; Lu X
    J Mol Model; 2012 Jun; 18(6):2599-611. PubMed ID: 22076061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced catalytic activity of human CYP2C9 natural alleles for gliclazide: molecular dynamics simulation and docking studies.
    Banu H; Renuka N; Vasanthakumar G
    Biochimie; 2011 Jun; 93(6):1028-36. PubMed ID: 21356265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural dynamics of the cooperative binding of small inhibitors in human cytochrome P450 2C9.
    Cai J; Shi R
    J Mol Graph Model; 2022 Jun; 113():108151. PubMed ID: 35168147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of ligand selectivity in CYP3A7 by molecular dynamics simulations.
    Fan JR; Zheng QC; Cui YL; Li WK; Zhang HX
    J Biomol Struct Dyn; 2015; 33(11):2360-7. PubMed ID: 26065334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intramolecular heme ligation of the cytochrome P450 2C9 R108H mutant demonstrates pronounced conformational flexibility of the B-C loop region: implications for substrate binding.
    Roberts AG; Cheesman MJ; Primak A; Bowman MK; Atkins WM; Rettie AE
    Biochemistry; 2010 Oct; 49(40):8700-8. PubMed ID: 20815369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The stereoselectivity of CYP2C19 on R- and S-isomers of proton pump inhibitors.
    Tian C; Zhu L; Yu D; Cao Z; Kang T; Zhu R
    Chem Biol Drug Des; 2014 May; 83(5):610-21. PubMed ID: 24350826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-A resolution.
    Wester MR; Yano JK; Schoch GA; Yang C; Griffin KJ; Stout CD; Johnson EF
    J Biol Chem; 2004 Aug; 279(34):35630-7. PubMed ID: 15181000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Membrane position of ibuprofen agrees with suggested access path entrance to cytochrome P450 2C9 active site.
    Berka K; Hendrychová T; Anzenbacher P; Otyepka M
    J Phys Chem A; 2011 Oct; 115(41):11248-55. PubMed ID: 21744854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure and dynamics of the membrane-bound cytochrome P450 2C9.
    Cojocaru V; Balali-Mood K; Sansom MS; Wade RC
    PLoS Comput Biol; 2011 Aug; 7(8):e1002152. PubMed ID: 21852944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Substrate selectivity of human cytochrome P450 2C9: importance of residues 476, 365, and 114 in recognition of diclofenac and sulfaphenazole and in mechanism-based inactivation by tienilic acid.
    Melet A; Assrir N; Jean P; Pilar Lopez-Garcia M; Marques-Soares C; Jaouen M; Dansette PM; Sari MA; Mansuy D
    Arch Biochem Biophys; 2003 Jan; 409(1):80-91. PubMed ID: 12464247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling and synthesis of novel tight-binding inhibitors of cytochrome P450 2C9.
    Peng CC; Rushmore T; Crouch GJ; Jones JP
    Bioorg Med Chem; 2008 Apr; 16(7):4064-74. PubMed ID: 18255300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part II.
    Mo SL; Zhou ZW; Yang LP; Wei MQ; Zhou SF
    Curr Drug Metab; 2009 Dec; 10(10):1127-50. PubMed ID: 20167000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytochrome P450 2C9 type II binding studies on quinoline-4-carboxamide analogues.
    Peng CC; Cape JL; Rushmore T; Crouch GJ; Jones JP
    J Med Chem; 2008 Dec; 51(24):8000-11. PubMed ID: 19053752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular modeling used to evaluate CYP2C9-dependent metabolism: homology modeling, molecular dynamics and docking simulations.
    Mendieta-Wejebe JE; Correa-Basurto J; García-Segovia EM; Ceballos-Cancino G; Rosales-Hernández MC
    Curr Drug Metab; 2011 Jul; 12(6):533-48. PubMed ID: 21486213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipophilicity relationships in inhibitors of CYP2C9 and CYP2C19 enzymes.
    Lewis DF; Lake BG; Ito Y; Dickins M
    J Enzyme Inhib Med Chem; 2006 Aug; 21(4):385-9. PubMed ID: 17059170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Probing small-molecule binding to cytochrome P450 2D6 and 2C9: An in silico protocol for generating toxicity alerts.
    Rossato G; Ernst B; Smiesko M; Spreafico M; Vedani A
    ChemMedChem; 2010 Dec; 5(12):2088-101. PubMed ID: 21038340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of metabolism by cytochrome P450 2C9: alignment and docking studies of a validated database of substrates.
    Sykes MJ; McKinnon RA; Miners JO
    J Med Chem; 2008 Feb; 51(4):780-91. PubMed ID: 18237107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I.
    Mo SL; Zhou ZW; Yang LP; Wei MQ; Zhou SF
    Curr Drug Metab; 2009 Dec; 10(10):1075-126. PubMed ID: 20167001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potentially increasing the metabolic stability of drug candidates via computational site of metabolism prediction by CYP2C9: The utility of incorporating protein flexibility via an ensemble of structures.
    Danielson ML; Desai PV; Mohutsky MA; Wrighton SA; Lill MA
    Eur J Med Chem; 2011 Sep; 46(9):3953-63. PubMed ID: 21703735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.